Sex Difference in the Impact of Steatotic Liver Disease on Incident Hepatocellular Carcinoma in Patients with Chronic Hepatitis B

Background and Aims: Until now, according to the EASL Clinical Practice Guidelines on the management of chronic hepatitis B (CHB), the relationship between steatotic liver disease (SLD) and the risk of hepatocellular carcinoma (HCC) in CHB patients still yields conflicting results, with some data suggesting an increased risk of HCC, while several cohort studies have indicated a reduced risk in CHB patients with SLD. Sex is a predominant factor in the development and severity of chronic liver diseases. We aimed to understand the effect modification by sex in this association using a large population-based cohort study with long-term follow-up of patients with CHB. Approach and Results: This population-based study from Taiwan’s National Health Insurance Research Database (2009–2022) comprised two cohorts of patients with CHB aged 40–75 years: (1) 53,888 patients treated with entecavir or tenofovir, and (2) 525,109 antiviral-naive patients. HCC was identified in 4245 and 9491 patients in the treated and untreated cohorts, respectively. After adjusting for competing risk of death and relevant covariates, SLD was associated with a lower risk of HCC in males but a higher risk in females, and this sex difference (p < 0.0001 for sex–SLD interaction) was identified in both treated (subdistribution hazard ratio [SHR] [95% CI]: 0.85 [0.74–0.96] in males and 1.42 [1.17–1.73] in females) and untreated (0.75 [0.67–0.84] in males and 1.34 [1.14–1.56] in females) patients. Using propensity score matching with stratification by sex, further accounting for differences in medication use between SLD and non-SLD groups, yielded consistent results. The excess risk of HCC with SLD among females was mainly in those aged≥55 years, and even existed in the presence of diabetes, whereas among males, SLD exhibited an inverse association with HCC, regardless of age or diabetes. Conclusions: There was a sex disparity in the association between SLD and CHB-related HCC. Future studies and management of SLD for CHB should consider the sex disparity.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-09-06
DOI
https://doi.org/10.3390/cancers18172880
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Sex Difference in the Impact of Steatotic Liver Disease on Incident Hepatocellular Carcinoma in Patients with Chronic Hepatitis B

Wan‐Jung Wu, Chih‐Lin Lin, Ming‐Whei Yu, Jyh‐Ming Liou et al.
Cancers
Liver Disease Diagnosis and Treatment
article

Sex Difference in the Impact of Steatotic Liver Disease on Incident Hepatocellular Carcinoma in Patients with Chronic Hepatitis B

Wan‐Jung Wu, Chih‐Lin Lin, Ming‐Whei Yu, Jyh‐Ming Liou, Chun‐Jen Liu, Jui‐Ting Hu, Chih-Hsuan Tien
article en

Abstract

Background and Aims: Until now, according to the EASL Clinical Practice Guidelines on the management of chronic hepatitis B (CHB), the relationship between steatotic liver disease (SLD) and the risk of hepatocellular carcinoma (HCC) in CHB patients still yields conflicting results, with some data suggesting an increased risk of HCC, while several cohort studies have indicated a reduced risk in CHB patients with SLD. Sex is a predominant factor in the development and severity of chronic liver diseases. We aimed to understand the effect modification by sex in this association using a large population-based cohort study with long-term follow-up of patients with CHB. Approach and Results: This population-based study from Taiwan’s National Health Insurance Research Database (2009–2022) comprised two cohorts of patients with CHB aged 40–75 years: (1) 53,888 patients treated with entecavir or tenofovir, and (2) 525,109 antiviral-naive patients. HCC was identified in 4245 and 9491 patients in the treated and untreated cohorts, respectively. After adjusting for competing risk of death and relevant covariates, SLD was associated with a lower risk of HCC in males but a higher risk in females, and this sex difference (p < 0.0001 for sex–SLD interaction) was identified in both treated (subdistribution hazard ratio [SHR] [95% CI]: 0.85 [0.74–0.96] in males and 1.42 [1.17–1.73] in females) and untreated (0.75 [0.67–0.84] in males and 1.34 [1.14–1.56] in females) patients. Using propensity score matching with stratification by sex, further accounting for differences in medication use between SLD and non-SLD groups, yielded consistent results. The excess risk of HCC with SLD among females was mainly in those aged≥55 years, and even existed in the presence of diabetes, whereas among males, SLD exhibited an inverse association with HCC, regardless of age or diabetes. Conclusions: There was a sex disparity in the association between SLD and CHB-related HCC. Future studies and management of SLD for CHB should consider the sex disparity.

CancersVol. 18(17)
Fu Jen Catholic University (TW), National Taiwan University (TW), Taipei City Hospital (TW), Cathay General Hospital (TW), National Taiwan University Hospital (TW)
Openalex Percentile: Top 10%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.